NOVO NORDISK A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 903.3 DKK | -1.05% |
|
+2.28% | +29.39% |
| 06:01am | Genetic profile may predict best response to weight-loss drug Wegovy | RE |
| 05-17 | Roche: share price stands out, Deutsche Bank in support | CF |
| Sales 2024 * | 289B 42.22B 3,323B | Sales 2025 * | 349B 50.93B 4,008B | Capitalization | 4,007B 584B 45,996B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.22B 1,198B | Net income 2025 * | 127B 18.47B 1,454B | EV / Sales 2024 * | 13.9 x |
| Net Debt 2024 * | 13.34B 1.95B 153B | Net cash position 2025 * | 12.63B 1.84B 145B | EV / Sales 2025 * | 11.4 x |
| P/E ratio 2024 * |
38.9
x | P/E ratio 2025 * |
31.9
x | Employees | 66,015 |
| Yield 2024 * |
1.31% | Yield 2025 * |
1.57% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | +2.28% | ||
| Current month | +0.08% | ||
| 1 month | +4.28% | ||
| 3 months | +5.28% | ||
| 6 months | +30.10% | ||
| Current year | +29.39% |
1 week
883.20
927.00
1 month
826.70927.00
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.30932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.40% | ||
| 10.45% | 5 M€ | +14.54% | ||
| 5.40% | 17 M€ | +8.10% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 903.3 | -1.05% | 2,115,167 |
| 16/05/24 | 912.9 | -0.46% | 3,350,700 |
| 15/05/24 | 917.1 | +0.78% | 2,120,311 |
| 14/05/24 | 910 | +0.01% | 3,118,148 |
Delayed Quote Nasdaq Copenhagen, May 17, 2024 at 03:59 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 584B | |
| +32.09% | 693B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- NOVO B Stock
